Geode Capital Management’s Kairos Pharma KAPA Stock Holding History

Geode Capital Management’s Portfolio KAPA Stock Details KAPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-11,275	Closed	-$30.3K	–	4539
2026 Q2	$30.3K	Sell	11,275 -4,624	-29%	-$16.8K	﹤0.01%	4326
2026 Q1	$62.2K	Buy	15,899 +5,494	+53%	+$25.8K	﹤0.01%	4264
2025 Q4	$51.7K	Buy	10,405 +1,005	+11%	+$6.58K	﹤0.01%	4227
2025 Q3	$77K	Buy	9,400 +6,285	+202%	+$50.3K	﹤0.01%	4192
2025 Q2	$15.5K	Buy	3,115 +196	+7%	+$998	﹤0.01%	4393
2025 Q1	$19.1K	Buy	+2,919	New	+$26.2K	﹤0.01%	4355

Other funds holding KAPA

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management's KAPA Position: Q3 2026 in Review

Geode Capital Management sold out of Kairos Pharma (KAPA) in Q3 2026, closing a stake of 11,275 shares — an estimated $30.3K sold.

Geode Capital Management first reported a position in KAPA in Q1 2025 and held it in 6 quarters. The position peaked at $77K in Q3 2025. 2 funds tracked by Wall St. Rank hold KAPA as of Q3 2026.

Geode Capital Management reported no remaining Kairos Pharma position as of Q3 2026 after selling out during the quarter.
Geode Capital Management sold 11,275 Kairos Pharma shares in Q3 2026, an estimated $30.3K.
Geode Capital Management first reported a position in Kairos Pharma in Q1 2025 and held it in 6 quarters.
Geode Capital Management's Kairos Pharma position peaked at $77K in Q3 2025.
2 funds tracked by Wall St. Rank held Kairos Pharma as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.